Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide
Authors
Keywords
-
Journal
PROSTATE
Volume 76, Issue 16, Pages 1484-1490
Publisher
Wiley
Online
2016-07-12
DOI
10.1002/pros.23232
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer
- (2017) Cynthia L. Gong et al. Journal of the National Comprehensive Cancer Network
- Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy
- (2016) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs
- (2016) Scott D. Ramsey et al. JAMA Oncology
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
- (2015) M. Nakazawa et al. ANNALS OF ONCOLOGY
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
- (2015) Wendy Onstenk et al. EUROPEAN UROLOGY
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
- (2015) Howard I. Scher et al. PLoS One
- Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
- (2015) Yuanyuan Qu et al. Scientific Reports
- Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care
- (2014) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Cancer Drug Prices in the United States: Reasons and Proposed Solutions
- (2014) Hagop Kantarjian et al. Journal of Oncology Practice
- Enzalutamide for the treatment of prostate cancer
- (2013) Sumanta K Pal et al. EXPERT OPINION ON PHARMACOTHERAPY
- New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
- (2013) Leslie Wilson et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
- (2009) Bruce E. Hillner et al. JOURNAL OF CLINICAL ONCOLOGY
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started